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In the Tokat and Sivas provinces of Turkey, the overall 
Crimean-Congo hemorrhagic fever virus (CCHFV) sero-
prevalence was 12.8% among 782 members of a high-risk 
population. CCHFV seroprevalence was associated with 
history of tick bite or tick removal from animals, employ-
ment in animal husbandry or farming, and being >40 years 
of age.
C
rimean-Congo hemorrhagic fever virus (CCHFV) in-
fection was ﬁ  rst deﬁ  ned in Turkey in 2003 from per-
sons who became sick during a 2002 CCHFV outbreak 
(1,2). During 2002–2007, CCHFV was conﬁ  rmed serologi-
cally, virologically, or by both types of testing, in ≈1,800 
persons, mainly in the Tokat and Sivas provinces of Turkey 
(Figure 1) (3). This region was then considered an epicen-
ter for CCHFV epidemics (4). This study determined the 
seroprevalence of CCHFV in a high-risk population living 
in  that region after 4 epidemic seasons and assessed trans-
mission routes of CCHFV infection. 
The Study
In June and September 2006, persons living in 56 
villages of the 14 districts of Tokat and Sivas provinces 
(Figure 1) who had a risk for CCHFV infection other than 
occupational risk (i.e., healthcare, slaughterhouse work, 
and veterinary care) were randomly selected for the study. 
Villages and districts were selected based on residences of 
patients who were diagnosed with CCHFV infection and 
treated at Cumhuriyet University Hospital, Sivas, Turkey, 
during the 2005 CCHFV outbreak. Men and women were 
included in the study, but children <7 years of age were 
excluded because of difﬁ  culties in drawing blood samples 
and obtaining parental consent.
Using EPI Info version 6 software (Centers for Disease 
Control and Prevention, Atlanta, GA, USA) and assuming 
a CCHFV seroprevalence of 10% in the study population 
with 99% conﬁ  dence levels, we calculated error limits of 
± 3% and a design effect of 1. The estimated sample size 
required was 664, but the target sample size of high-risk 
persons was increased to 782. Another 100 persons who 
were not at high risk for CCHFV infection, but who lived 
in urban areas in the high-risk region and agreed to provide 
blood samples, were also included in the study. The study 
protocol was approved by the Cumhuriyet University Hos-
pital Human Ethics Committee.
The CCHFV Seroprevalence Study Team in Turkey 
included a physician and a nurse who went to the selected 
villages and approached the heads of the village and se-
lected families. They explained the objectives of the study 
and asked for written informed consent from participants 
or parents of participating minors and then administered an 
interview-based questionnaire and collected a blood sam-
ple. The questionnaire considered the following variables: 
age; sex; history of tick bite, tick removal from animals, 
animal abortion, and animal slaughtering activity; close 
contact with a CCHFV patient or an animal; and occupa-
tion. Blood samples (10 mL each) were collected and later 
tested for antibodies to CCHFV by using immunoglobulin 
G (IgG) ELISA kits (Vector-Best; Kolsovo, Novosibirsk, 
Russia). SPSS version 10.0 (SPSS, Chicago, IL, USA) for 
Windows software was used for statistical analysis. Chi-
square and Fisher exact tests were used to compare cat-
egorical variables. Statistical signiﬁ  cance was deﬁ  ned as 
a 2-tailed p value <0.05. Univariate analysis was used to 
identify the risk factors for seropositivity of CCHFV in the 
782 participants.
Of the 782 high-risk persons, 100 were positive for 
IgG against CCHFV (seroprevalence 12.8%). The sex ratio 
was ≈1:1 (390 females, 392 males). Forty-seven (12.1%) 
of 390 female participants and 53 (13.5%) of 392 male 
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Figure 1. Districts of Tokat and Sivas provinces, Turkey, from which 
782 persons at high risk for Crimean-Congo hemorrhagic fever 
virus infection were sampled, 2006. Sample sites are indicated by 
black dots. (Map provided by Zati Vatansever and reproduced with 
permission.) participants were seropositive for CCHFV (p>0.05). Mean 
age was 41.5 years. Of the 100 serum samples collected 
in the urban population, only 2 (males 44 and 56 years of 
age) were seropositive. The CCHFV seroprevalence in the 
782 persons at high risk increased signiﬁ  cantly with age 
(p<0.001). The highest proportion (23.5%) of seroposi-
tivity was found in persons 61–70 years of age (p<0.001) 
(Table 1). Figure 2 shows distribution of the CCHFV se-
roprevalence in high-risk persons by age groups. The only 
variables signiﬁ  cantly associated with presence of antibody 
against CCHFV were history of tick bite (p = 0.002) or of 
tick removal from the animals (p = 0.03), employment in 
animal husbandry (p = 0.01) or farming (p = 0.02), and age 
>40 years (p<0.001) (Table 2).
Conclusions
Serologic evidence of CCHFV in Turkey was report-
ed in the 1970s (4). In 2003, the CCHFV seroprevalence 
among 40 veterinarians in the Tokat region was 2.5% (5). 
Another seroprevalence study conducted in 2003 among 
healthcare workers providing care to CCHFV patients in 
Turkey detected no seropositive persons (6). The present 
survey indicates that the seroprevalence of CCHFV is high-
er in persons living in rural areas than in urban areas of the 
CCHFV epicenter in Turkey (12.8% vs 2.0%). However, 
because special markets for animal trading are located on 
the outskirts of large cities in Iran, CCHFV seroprevalence 
was found to be higher among persons living in urban ar-
eas than in persons living in rural areas of this country (7). 
Living in a rural area is a risk factor for exposure to the 
tick vector and for acquiring CCHFV infection (8,9). Ex-
pected seroprevalence of CCHFV among high-risk persons 
during epidemics has been found to be 10% (3); however, 
seroprevalence has been reported to be as low as 0.5% in 
nonepidemic situations (10). Other studies conducted in ru-
ral parts of Iran and Senegal during epidemics showed that 
the CCHFV seroprevalence was 13%, comparable to our 
ﬁ  ndings (9,11).
In the present study, history of tick bite and history of 
tick removal from animals were found to be signiﬁ  cantly 
associated with CCHFV seropositivity. The overall tick-
bite frequency was 62% (483/782) among persons at high 
risk and has been reported among 40%–60% of CCHFV 
patients in Turkey (4). We also determined that the occupa-
tions of animal husbandry and farming were signiﬁ  cantly 
associated with CCHFV seropositivity. Vector ticks are 
generally present on the ground and on animals, which ex-
plains the risk for CCHFV infection in persons who work 
in farming and animal husbandry. Personal protective mea-
sures such as regular examination of clothing and skin for 
ticks, tick removal, and use of repellents are important to 
prevent CCHFV infection (12).
We did not identify any association between sero-
prevalence and gender but found that CCHFV seropositiv-
ity increased with age. In these regions of Turkey, women 
contribute to farming and animal husbandry tasks and are 
exposed to ticks and livestock as often as men are. Howev-
er, age >40 years was signiﬁ  cantly associated with CCHFV 
seropositivity and reﬂ  ects the age of workers in Turkish ag-
ricultural areas (4,8,13). Increased CCHFV seroprevalence 
with age may result from increased opportunities of contact 
with vector ticks (14).
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Table 1. Demographics and seroprevalence of CCHFV in persons living in rural and urban areas of Tokat and Sivas provinces, 
Turkey, 2006* 
Characteristic Persons living in rural area (n = 782)  Persons living in urban area (n = 100) 
Age, y 
  Mean ± SD  41.5 ± 18.6  41.9 ± 18.4 
 Range  7–83 7–80
Gender, no. (%) 
  Female  390 (49.8)  53 (53) 
  Male  392 (50.2)  47 (47) 
Total seroprevalence, no. positive (%)  100 (12.8)  2 (2) 
Seroprevalence by gender, no. positive/no. tested (%)† 
  Female  47/390 (12.1)  0/53 (0) 
  Male  53/392 (13.5)  2/47 (4.3) 
Seroprevalence by age, y, no. positive/no. tested (%)‡ 
  7–20  4/138 (2.9)  0/14 (0) 
  21–30  9/100 (9)  0/18 (0) 
  31–40  14/134 (10.5)  0/15 (0) 
  41–50  20/126 (15.90  1/18 (5.6) 
 51–60  23/157  (14.6)  1/17(5.9) 
  61–70  20/85 (23.5)  0/13 (0) 
  71–83  10/45 (22.2)  0/5 (0) 
*CCHFV, Crimean-Congo hemorrhagic fever virus.  
†p value = 0.59 for persons living in rural area; for persons living in urban area, data are insufficient for statistical analysis.
‡p value <0.001 for persons living in rural area; for persons living in urban area, data are insufficient for statistical analysis.Crimean-Congo Hemorrhagic Fever Virus
Exposure to blood and tissues of viremic animals dur-
ing slaughter is a source of infection (12,14). However, we 
did not identify any association between CCHFV seropos-
itivity and contact with animals. This ﬁ  nding may result 
from a low number of viremic animals in our study region. 
It is known that domestic animals generally have low levels 
of viremia, which lasts a short time (15). However, in our 
study region, 79% of animals have been found to be sero-
positive against CCHFV (4). 
In the study population, 89 (11.4%) persons had a 
history of close contact with a CCHFV-infected patient. 
Among these 89 persons, 14 (15.7%) were seropositive, 
but this transmission route for CCHFV was not statistically 
signiﬁ  cant for our study population. However, protection 
against this potential transmission route is especially im-
portant for healthcare workers in hospitals that provide care 
to CCHFV case-patients (12).
This study indicated that tick exposure is the most 
statistically signiﬁ  cant transmission route for CCHFV in a 
high-risk population in Turkey. Effective tick prevention 
aids such as tick repellents may help reduce the risk. On the 
other hand, the absence of CCHFV seropositivity in 87.2% 
of the population after 4 CCHFV outbreaks in Turkey may 
suggest that this population remains at risk for infection 
in the future. This knowledge may help public health au-
thorities determine appropriate CCHFV intervention and 
prevention methods. 
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